A phase II clinical trial of SkQ1 in Leber's hereditary optic atrophy (LHON)
Latest Information Update: 21 Dec 2021
At a glance
- Drugs Plastoquinonyl-decyl-triphenylphosphonium (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Therapeutic Use
- 16 Dec 2021 According to a Mitotech media release, the company is planning to start this Phase 2 with Visomitin in LHON in 2022 in collaboration with the LHON clinic at the Doheny Eye Institute at the University of California Los Angeles (UCLA).
- 04 Mar 2021 New trial record
- 26 Feb 2021 According to a Mitotech media release, the company expects to initiate this study in 2021.